Immutep (IMMP) Return on Capital Employed (2017 - 2024)
Immutep's (IMMP) quarterly Return on Capital Employed came in at 64.24% in Q4 2024, down 1013.0% YoY from 7.04% in Q1 2024, and up 11.07% on a QoQ basis from 72.24% in Q2 2024.
Immutep (IMMP) Return on Capital Employed (2017 - 2024) Analysis & Trends
Immutep (IMMP) has 7 years of Return on Capital Employed data on file, last reported at 64.24% in Q4 2024.
- Quarterly Return on Capital Employed fell 1013.0% year-over-year to 64.24% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 64.24% (down 1013.0% YoY) and the FY2025 annual result came in at 36.23%, down 803.0% from the prior year.
- Return on Capital Employed advanced to 64.24% in Q4 2024, from 72.24% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 54.11% in Q4 2023 to a low of 76.24% in Q4 2022.
- A 4-year average of 64.37% and a median of 64.24% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 2121 bps — and 2023, when it soared 2214 bps.
- Tracing IMMP's Return on Capital Employed over 4 years: stood at 55.03% in 2021, then plunged by 39 bps to 76.24% in 2022, then rose by 29 bps to 54.11% in 2023, then retreated by 19 bps to 64.24% in 2024.
- The last three Return on Capital Employed figures came in at 64.24% (Q4 2024), 72.24% (Q2 2024), and 54.11% (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -64.24% |
| Jun 30, 2024 | -72.24% |
| Dec 31, 2023 | -54.11% |
| Dec 31, 2022 | -76.24% |
| Dec 31, 2021 | -55.03% |
| Dec 31, 2019 | -117.23% |
| Jun 30, 2019 | -98.26% |
| Dec 31, 2018 | -45.03% |
| Jun 30, 2017 | -36.91% |
| Mar 31, 2017 | -33.84% |